Developing type 2 diabetes (T2D) can increase patient risk of developing other common diseases and exacerbate their severity, including diseases that affect bone and joints. Such comorbidity interactions are hard to study in detail by traditional endocrinological methods. Thus, we developed tissue transcript analytical approaches to identify common pathways through which these diseases can interact. We examined RNAseq and microarray transcript datasets from studies of T2D and chronic bone and joint diseases, namely rheumatoid arthritis (RA), osteoarthritis (OA), juvenile idiopathic arthritis (JIA) and low peak bone density, a key osteoporosis (OP) determinant. These datasets contained data from affected individuals and matched controls. Differentially expressed genes (DEGs) for each condition were compared with T2D DEG. Overlapping DEGs (i.e., those common to T2D and a bone or joint condition) were subjected to gene enrichment by pathway analyses and by gene ontology methods, and the results were evaluated by using SNP-disease linkage (dbGaP) and gene-disease association (OMIM) databases that indicate gene involvement in pathologies. By examining gene targets of transcription factors (TFs) and microRNA (miRNAs), we also constructed DEG-TF and DEG-miRNA interactions networks for analysis. We identified strong candidate genes in common pathways, notably including SYK, UCP3, ROR1, PPARG, BUB1, AKT2, ADCY2 and CCR5. The DEG-TF network and DEG-miRNA interactions network analyses revealed a number of TFs (GATA2, FOXC1, USF2, YY1, E2F1, JUN, RELA, CREB1, TFAP2A, NFB1) and miRNAs (mir-335-5p, mir-16-5p, mir-26b-5p, mir-124-3p, mir-218-5p, mir-98-5p, mir-29b-3p, mir-3135b, mir-29c-3p, mir-1-1) that can regulate the identified DEGs at the transcriptional and post-transcriptional levels. Thus this data-driven approach has enabled identification and validation of regulatory factors and cell pathways by which T2D may influence bone and joint conditions, which may suggest new ways to interfere with the pathogenic processes involved.
I. INTRODUCTION
Type 2 diabetes (T2D) affects hundreds of millions of people and has become an enormous clinical problem with serious The associate editor coordinating the review of this manuscript and approving it for publication was Derek Abbott . attendant vascular disease issues, including heart disease, strokes, retinopathy and peripheral ischemia. The high incidence of T2D and its tendency to affect the function of many organs makes it important to determine how T2D interacts with co-morbidities, i.e., other diseases suffered by the same individual at the same time [1] . This is an important issue for the management of the co-morbidities and in determining whether a T2D therapy may affect those co-existing conditions. T2D-associated features of particular concern include increased body weight and fat composition, chronic secretion of inflammatory hormones and high circulating levels of glucose and glycated proteins that cause vascular damage [1] , [2] . In addition there are the local cellular effects of insulin resistance itself. These affect diseases of bone and joints, the commonest of which include osteoporosis, osteoarthritis and inflammatory types of arthritis such as rheumatoid arthritis (RA) [3] . It is not well understood how the development and progression of these diseases are influenced by T2D. Disease interactions are typically studied by endocrinological approaches, such as methods that focus on T2D-associated cell secretions, of high serum glucose and of glycation product. Here, we employed a computation-based approach that utilized gene expression data, seeking to identify any gene pathways that are common to T2D and these bone and joint diseases. While not all processes occur at the same time (e.g., T2D may influence the early stage of development of a bone disease but not later stages), nevertheless gene expression is profoundly affected by the pathological processes and reveals information about pathways shared by the diseases. We therefore identified pathways that overlap in T2D and bone/joint diseases and so may have clinical utility. This approach may also identify important pathways that are relevant to a range of other diseases.
Osteoporosis (OP) is a disorder that weakens the bone and makes it vulnerable to low trauma fracture. The hallmark of OP is low bone mineral density (BMD), identified by X-ray absorptiometry [4] . After early adulthood, BMD of individuals decline (as in other mammalian species), and many factors aggravate this over time, such as diminishing sex hormone levels as well as circulating inflammatory hormones. An important determinant of OP in old age is peak the BMD level attained during early adulthood, a high point from which BMD declines. T2D also greatly increases risk of fracture, even though it does not always affect BMD, which may reflect bone incorporation o T2D glycation products that affect bone material strength [5] , [6] . Bone health can also be impaired by T2D medications such as rosiglitazone. Thus, new approaches to identify such overlapping problems due to shared common pathways will greatly inform treatment. A similar approach may be useful in considering how T2D interacts with joint diseases.
RA is an inflammatory joint condition with painful joint swelling, synovial membrane hyperplasia and local bone damage, destroying the local bone and joint architecture to cause severe pain and impaired mobility. An important treatment option is the use of anti-inflammatory drugs. T2D is a risk factor for inflammatory arthritis and, conversely, RA is a risk factor for T2D, with disease modifying anti-rheumatic drugs ameliorating T2D [7] , [8] . Other inflammatory forms of arthritis such as juvenile idiopathic arthritis (JIA) are also major clinical challenges [9] . Osteoarthritis (OA) is the most common joint disease but is not typically inflammation-associated at presentation (although inflammation is a significant influence in early stages of OA development), rather it involves progressive damage and erosion of joint cartilage [10] , [11] . This can be induced by joint damage or instability and high mechanical load. Surprisingly, meta-analysis studies clearly implicate T2D as an independent risk factor for OA and in rodent models of OA untreated T2D results in much more severe OA joint that non-diabetic controls [12] . As with OP, while T2D interactions with OA, JIA and RA have been studied, we lack any description of cell pathways common to their presentation and pathophysiologies.
To address these issues we studied transcript datasets to identify pathways in cells and tissues that are commonly affected by both T2D and diseases of bone and joints. Utilizing computational analysis of global transcriptomes, we identified and characterized the gene expression profiles seen in T2D and in RA, OA, OP and JIA from their common gene expression patterns. We cross-compared this data with pathways previously identified and validated in publicly available resources such as dbGaP and Online Mendelian Inheritance in Man (OMIM), as well as protein-protein interaction (PPI) datasets [13] , [14] . Our network-based approach thus enabled us to identify common pathways with pathological potential that may influence the progression of bone and joint diseases.
II. MATERIALS AND METHODS

A. OVERVIEW OF ANALYTICAL APPROACH
The schematic diagram in Fig. 1 summarises our methodology which constitutes a quantitative systematic approach that can be used to evaluate comorbidity interaction using a variety of gene expression datasets. This methodology comes in gene expression analytics that are validated using FIGURE 1. The schematic diagram of the network-based methodology employed in this study. The high-throughput transcriptomics datasets (RNA-Seq and/or microarray) of T2D, RA, OA, OP, JIA were obtained from Gene Expression Omnibus and EBI ArrayExpress databases. The differential expression analysis was performed on the transcriptomics analysis. The DEseq2 package was utilized to identify differentially expressed genes (DEGs) from RNA-Seq and Limma package was used to identify DEGs from microarray genes expression datasets. Then, we screened those DEGs which were mutually expressed in T2D and RA, OA, OP, JIA. These identified DEGs were further subjected to clarify the biological significance using gene ontology, pathways analysis. The protein-protein interactions analysis around the proteins encoded by the common/mutual DEGs were studied to identify the key signaling molecules termed ''hub protein'' by topological measures. The regulatory biomolecules consisting of transcription factors (TFs) and microRNAs (miRNAs) were identified from the DEGs-TFs and DEGs-miRNAs network analysis. signal pathway information, Gene Ontology (GO) data, disease-gene associations as well as protein-protein interaction data. These allow not only the identification of possible pathways components common to comorbidities but information as to any known pathogenic potential of these pathways.
B. DATASETS EMPLOYED IN THIS STUDY
To investigate molecular pathways common to T2D and RA, OA, OP, and JIA, we first analyzed global transcriptome analyses (RNAseq) and gene expression microarray datasets. We, therefore, collected raw data from the Gene Expression Omnibus of the National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/geo/) and EBI array express (https://www.ebi.ac.uk/arrayexpress/). We selected 5 large human gene expression datasets to use in this study; these datasets had accession numbers E-MTAB-5060, GSE114007, GSE55457, GSE7158, and E-GEOD-71595. E-MTAB-5060 is an RNAseq dataset obtained from pancreatic islet cell studies of healthy and T2D individuals. GSE114007 is an RNAseq dataset derived from OA and normal human knee articular cartilage. GSE55457 is an Affymetrix DNA array dataset from a study of normal, OA and RA synovial tissues; the OA data in this set was not employed as OA primarily affects articular cartilage. GSE7158 is an Affymetrix DNA array-based study of blood cells from outlier high and low peak bone mass females aged 20-45; while these were not OP sufferers at the time of transcript analysis the latter individuals are at greater risk of OP as they age compared to the former group. It should be noted that the original study (and dataset generation) focused on individuals at the key age period as they undergo bone changes that later affect their bone health. E-GEOD-71595 was from an RNAseq study of CD4+ cells obtained from auto-immune/inflammatory type JIA patients and healthy controls.
C. ANALYSIS METHODS
Employing RNAseq and DNA microarrays technologies to perform global transcriptome analyses, gene expression profiles of T2D with that in our RA, OA, OP and JIA datasets were compared. These datasets were derived from studies that compared pathological and normal tissue s to identify DEGs that are associated with the respective disease. Our analytical pipeline employed the original unprocessed datasets with DESeq2 [15] and Limma [16] R Bioconductor packages which were designed for RNAseq and microarray data, respectively. In order to avoid issues inherent in comparison of gene expression data that is derived from different platforms and experimental systems, we normalized and calibrated data from all the samples (diseased or control) by Z-score transformation (Z ij ) for each disease-gene expression matrix using:
where SD is a standard deviation, g ij is the expression value of gene i in sample j. Such a transformation enables comparisons of gene expression across tissue samples and across disease categories. We thus used a Studentised t-test statistic to identify those genes that with altered expression associated with the individual disease states. Thus, the data were log 2 -transformed to determine differential expression, then unpaired t-tests performed used to reveal statistical differences in expression of those genes expressed in patients vs control (normal) tissue samples. Genes showing significant differences were then selected then further filtered using their observed log-fold change. Thus, genes of interest were those showing 1 log 2 change, with a p-value in the t-tests of < 5×10 −2 adjusted for multiple testing using the estimate of false discovery rate.
To investigate associations between gene expression and disease state, we used a neighborhood-based benchmarking and topological approaches [17] . We constructed gene-disease networks (GDNs) in which network nodes are either diseases or genes, forming a network that can be viewed as a bipartite graph. In this schema, two diseases are considered to have a connection when sharing at least one significantly dysregulated gene. Taking a particular set of human diseases D and a set of genes G, we attempt to determine whether gene g ∈ G is associated with disease d ∈ D. If G i and G j , the sets containing genes that are significantly altered in their expression (both up-and down-regulated) and are respectively associated with diseases i and j, then the number of shared expression-altered genes (n g ij ] associated with both diseases i and j is as follows:
Co-occurrence is a parameter that refers to how many shared dysregulated genes (i.e., DEGs) are in the GDN. Common neighbors are identified using the Jaccard Coefficient method [18] , [19] , where edge prediction scores for the node pair is:
where E refers to the set of all edges. We then estimate the disease comorbidity associations for these datasets by employing two of our R software packages ''comoR'' [20] which can computes and predicts novel estimators of the disease comorbidity associations and ''POGO'' [21] which computes the association disease comorbidity risks and patient stratification. Thus, in order to reveal the pathways active in T2D that are also found in the OA, RA, OP-related and JIA conditions, we employed pathway and gene ontology analysis with DAVID bioinformatics (https : //david − d.ncifcrf .gov/) and the KEGG pathway database [22] . In addition, we constructed protein-protein interaction (PPI) networks for the disease-pair datasets by means of information derived from the STRING resource [string-db.org]. We then incorporated two gold-benchmark curated disease datasets, OMIM (www.omim.org) and dbGaP (www.ncbi.nlm.nih.gov/gap), in order to provide proof of principle for the network-based approach described here.
D. DEG-TF INTERACTION NETWORK ANALYSIS: REGULATORY TRANSCRIPTION FACTORS
To determine whether common transcriptional regulatory elements of these DEGs exist, we investigated the transcription factors (TFs)-DEGs interactions network utilizing publicly available JASPAR database [23] . The network was subjected to topological analysis via using NetworkAnalyst [24] . We selected 10 TFs with the highest topological matrix (degree) as the regulatory TFs.
E. DEG-MIRNA INTERACTION NETWORK ANALYSIS: REGULATORY MICRORNAS
We also analyzed the DEGs-miRNAs interactions network utilizing experimentally verified miRNAs-target gene interactions from TarBase [25] and miRTarBase [26] database respectively to identify miRNAs that regulate the DEGs as the post-transcriptional level. The interactions were retrieved via NetworkAnalyst [23] . The top miRNAs with highest topological matrix degree were selected as the regulator of the identified DEGs.
III. RESULTS
A. DEG ANALYSIS OF DATASETS
DEGs were analyzed in the human RNAseq and microarray datasets selected, performing comparisons between disease T2D, RA, OP/low peak bone mass, OA and JIA tissue; these were performed using DESeq2 and Limma (Bioconductor packages). For each dataset DEG thus identified were statistically analyzed by the R Bioconductor packages noted below. DEGs were defined as genes with false discovery rate (FDR) under 0.05 and more than log 2-fold increase or decrease in gene expression The numbers of unfiltered DEG that were identified were, respectively, 1290 for T2D, 393 for OP, 2013 for OA, 833 for RA and 1003 for the JIA datasets.
We also performed comparison analysis to identify the common significant genes across T2D and bone and the different joint diseases. We observed T2D shares 5, 16, 4 and 19 significantly up-regulated genes and 34, 40, 4 and 9 significantly down-regulated genes with RA, OA, OP and JIA conditions respectively. To identify statistically significant associations between T2D and the other conditions, we constructed an up-and down-regulation diseasome relationship network that was centerd on T2D where two diseases are comorbid when one or more DEGs associated with both diseases are found (see Figure 1a and 1b). 2 particular significant genes, PLAU and GJA1 (which were, respectively, a serine protease and plasminogen activator, and a gap junction connector protein), are commonly up-regulated in T2D, OA and JIA, while 2 significant genes (BIRC3 and MX1, respectively an anti-apoptosis factor and a poorly understood interferon induced gene) are commonly up-regulated in T2D, RA and JIA tissues, and 1 significant gene (GAP43, a growth cell plasticity associated factor) is commonly up-regulated in T2D, RA and OA tissues. It was interesting to note that, only 1 gene (ELL2, an RNA polymerase gene) was commonly down-regulated among T2D, RA and OA.
DEG common to T2D and the bone and joint condition datasets (OA, RA, JIA and OP-related) were identified, and these are summarised graphically in Figs 2A and B , which shows genes with, respectively elevated and reduced expression. Note that some genes (e.g., PLAU and GAP43) are In the connection diagrams T2D forms the center of a connection web with the bone and joint diseases placed on the periphery and significant DEG indicated (green circles), with connecting lines linking the datasets undergoing comparison. In these figures the green circles are used to represent genes and red hexagons are used to represent diseases. The size of the hexagons is the proportion of the number of the associated genes.
found in more than one common dataset and are drawn with more than one edge.
B. FUNCTIONAL ENRICHMENT OF DEG SETS COMMON TO T2D AND BONE/JOINT DISEASES
We performed pathway and gene ontology analyses with the DEG sets with the DAVID online bioinformatics portal. For pathways we used KEGG data enrichment for T2D vs RA, T2D vs OA, T2D vs JIA and T2D vs OP. To combine transcriptome and proteome analyses, we went on to perform a regulation analysis to gain more insight into pathways associated with these common DEGs. In addition, we could use this approach to predict links to pathologically dysregulated pathways. These pathway analyses were performed using the KEGG pathway database (http://www. genome.j/kegg/pathway.html) and functional annotation analysis tool DAVID-v-6.8 (http://niaid.abcc.ncifcrf.gov) to identify over-represented pathway groups among the DEGs, as well as to put them into functional categories. Pathways that were identified as significantly enriched among the common DEGs (FDR <0.05) were filtered using a manual approach to include only genes with known relevance to the diseases concerned. These outcomes, summarised in Table 1 , included a number of relevant and significant pathways. For example in OA we found hormonal response pathway genes that included TNF, NF-κB, PPAR-gamma and TGF-β pathways, many of which were shared with JIA.
To obtain better insights into the pathways that we identified, the enriched common DEG sets were processed using a gene ontology approach employing EnrichR (http://amp. pharm.mssm.edu/Enrichr/) which identifies biological processes that are related. The list of processes identified in this way were curated to reveal those with a known involvement in bone and joint diseases and T2D. These processes and the associated genes are summarised in Table 2 . We found a variety of pathways that notably included mineralization, glucose metabolism and BMP functions that are relevant to bone physiology.
C. PROTEIN-PROTEIN INTERACTION (PPI) ANAYSIS TO IDENTIFY COMMON SUB-NETWORKS
Altered expression of proteins in a sub-network may identify such sub-networks as dysfunctional, at least in the context of these diseases. Indeed, multiple diseases may arise from the malfunction of a protein complex. Thus, two diseases may be related if sharing one or more protein sub-network. After identifying DEGs that are involved in pathways and processes common to T2D and bone/joint diseases of interest to our study, we looked for any evidence for previously identified sub-networks, based on previously reported PPI. With these enriched common disease-gene sets, we made PPI networks by the web-based visualization package STRING [27] . Sub-networks seen in T2D vs the bone/joint diseases are summarised in Fig. 3 . Gene clusters were determined from the Markov cluster algorithm (MCL); we noted that many TABLE 1. KEGG pathway analyses to identify pathways common to T2D and the bone and joint conditions revealed by the commonly expressed genes. These include significant pathways common to T2D and A) RA B) OA C) OP and D) JIA. TABLE 2. GO identification of biological processes that are common to T2D and the bone and joint diseases. KEGG pathway-enriched genesets were used for GO studies to identify processes that are in common between these pathologies. GO terms were curated to identify those relevant to the bone and joint function and pathology. Example pathways genes and pathway adjusted p-values are indicated. PPI sub-networks contained genes within one cluster, which is indicated in Fig. 3in red. This analysis suggests PPI sub-networks do exist in our enriched genesets, confirming the existence of relevant functional pathways.
D. CO-MORBIDITY ANALYSIS AND IDENTIFICATION OF SIGNIFICANT PATHWAY MARKER GENES
Significant pathways relevant to the common disease gene datasets are displayed in Fig. 4A with gene pathway links shown; here we have considered genes identified in T2D DEG and their connections with bone/joint disease DEG sets. Considering both the dysregulated gene expression seen in T2D and gene-disease associations, we set up gene-disease associations networks (GDN) in order to explore the pathology-shared genes and comorbidity networks (see Fig. 4B ). Beginning with from a bipartite graph we constructed biologically relevant network projections and multi-relational gene-disease networks where the nodes are either diseases or genes and edges indicate gene-disease association. This type of bipartite graph contains two disjointed sets of nodes; one of these relates to known genetic disorders and the other to genes identified as significant for T2D. Information related to disorders, disease genes (and their associations) that we employed were obtained from the OMIM and dbGaP. The GDN, nodes represent disease or genes such that two diseases are connected to each other where they share a gene with variants (usually single nucleotide polymorphisms) that have previously been demonstrated to be associated with both diseases (see Fig. 4B ). The number of such interlinked . Genes significant in T2D that are potential markers of bone and joint diseases. A) Enriched datasets from our analyses with links to processes and pathways revealed by our analysis. Gene names are in small circles; color indicates membership of clusters evident from MCL analysis B) Genes identified from OMIM and dbGaP databases using single nucleotide polymorphism association with diseases. The graphic summarises these genes that are also found in our analysis of T2D and the bone/joint conditions. In these figures the blue circles are used to represent genes and red hexagons are used to represent diseases. The size of the hexagons is the proportion of the number of the associated genes.
genes between T2D were typically between 2 and 25, with several being linked to more than one bone/joint disease, notably SYK, UCP3, ROR1 and PPARG (OA and JIA), BUB1 (OA and RA), AKT2, ADCY2 and CCR5 (RA and OP), ADCY2 and CCR5 (OA and OP) and CCR5 and ADCY2 (RA and JIA). These overlapping-set genes may be of particular priority for further study although their functions do not currently appear to overlap.
E. IDENTIFICATION OF TRANSCRIPTIONAL AND/OR POST-TRANSCRIPTIONAL REGULATORS
We studied the TFs-DEGs and miRNAs-DEGs networks to identify regulators of the DEGs at transcriptional and post-transcriptional levels (see Figure 5 and 6). The statistical analysis of the topological parameters revealed TFs (GATA2, FOXC1, USF2, YY1, E2F1, JUN, RELA, CREB1, TFAP2A, NFB1) and miRNAs (mir-335-5p, mir-16-5p, mir-26b-5p, mir-124-3p, mir-218-5p, mir-98-5p, mir-29b-3p, mir-3135b, mir-29c-3p, mir-1-1) as the principal regulators of the DEGs which were identified as shared by T2D and bone and joint conditions. 
IV. DISCUSSION
Our study helps to fill a significant gap in our knowledge about how T2D may be influencing the development of OA, RA, OP and JIA. Rather than using a directly mechanistic or endocrinological approach we looked for genes that appeared dysregulated in T2D and in one or more of the bone and joint diseases, using this information to give clues to identify aberrantly acting pathways and control mechanisms that might otherwise not be suspected to play a role in these diseases. This line of inquiry starts with an agnostic approach that employs a sequence of bioinformatics steps to analyze widely available resources and data and can easily be applied to a range of possible co-morbidities. The power and quality of the analysis can over time be further improved and augmented as more large disease-relevant gene expression datasets become available.
Using the combined analysis of transcriptomic, genetic, PPI, pathway and GO data, our disease network revealed a number of new putative disease relationships that has not been identified from earlier studies and analyses, These have the potential to inform and direct further clinical and biochemical studies of these co-morbidities. Our approach, in effect, takes advantage of the complexity that is usually such a barrier to conventional co-morbidity studies. Our underlying hypothesis is that once we construct a list of a reasonably large proportion of disease-related genes and pathways, we will be able to predict the susceptibility of individuals to other diseases using molecular biomarkers found using this approach. Combined with genetic data (e.g., SNP data) such information will be needed as a key element in developing accurate prognostic medicine. Our results here indicate that combining molecular and population-level data can provides insights that can lead to the generation of new hypotheses about the mechanisms that underlie disease development and comorbidity interactions. In addition, this approach can provide important information relevant to overlaps in medication that may have implications for patient care, and provide suggestions as to why these diseases are seen commonly as interacting comorbidities. This is known problem in particular for T2D, whose development is associated with worse outcomes for RA patients, an interaction seen in pre-clinical rodent models as well [12] .
Gene activity is regulated both at the transcriptional and at the post-transcriptional level. Thus, to provide deeper insights into the regulatory patterns of the identified genes, we analyzed the TFs-DEGs and miRNAs-DEGs networks. TFs drive the transcription of genes and may do so coordinately across genes with related functions. In contrast, miRNAs are particularly powerful regulators of transcript levels at the post-transcriptional level, although it should be noted that there are other classes of non-coding RNAs that are less potent and less well characterized that also affect transcript levels post-transcriptionally. We thus used targets of TF and miRNA to identify their targets among the DEGs that were involved in T2D and bone and joint diseases. Among the identified TFs, GATA2, FOXC1, USF2, YY1, E2F1, and JUN were previously identified as the regulators of DEGs in our previous report on Alzheimer's diseases by a network-based approach [28] . GATA2 is also implicated in early-onset coronary artery disease [29] . The dysregulation of FOXC1 is involved in skeletal abnormalities [30] . The USF2 is also involved in diabetic nephropathy [31] . Dysregulation of YY1 in the liver causes insulin resistance, dyslipidemia etc and has also been proposed as targeting hepatic YY1 an important target for insulin-resistant diabetes [32] . It has been suggested that E2F1 promotes the hyperglycemia during diabetes [33] . The JUN is involved in inflammatory and bone disease [34] . T2D is involved with dysregulated NFKB1 [35] . The involvement of the RELA is not found in the literature in T2D and bone and joint disease. CREB1 polymorphism is associated with T2D risk in the Chinese population [36] .
The genes that we found to commonly show dysregulation in T2D and with OP, RA, JIA and OA included some with known influences on T2D (or related metabolic phenomena) and the bone and joint diseases, but for some the common link was not clear. For example, UCP3 codes for a mitochondrial 'uncoupling factor' that affects cell metabolism; it uncouples oxidative phosphorylation from ATP synthesis, which can result in heat generation and can protect the mitochondria from oxidative stress. Mutations in UCP3 are associated with obesity [37] and indeed insulin regulate UCP3 expression [38] . UCP3 is not characterized as affecting bone but has been linked to cartilage cell survival which is clearly crucial for joints and may indirectly affect bone density [39] , [40] . SYK codes for a tyrosine kinase enzyme that is essential for embryo development and crucial to immune system function, notably B cells that are involved in many aspects of inflammation, however, only indirect links of SYK with bone physiology are known [41] . ROR1 codes for another tyrosine kinase of poorly understood function but is involved with cell response to hormones. However, ROR1 has known influences on bone forming cells although a role in joint biology and diabetes is unclear [42] , although there is data linking ROR1 to adipogenesis processes in vitro [43] . PPARG is a crucial nuclear receptor that is the target of glitazone compounds used to treat T2D, but also plays an important role in connective tissue function, especially bone osteoblast and smooth muscle formation [44] , [45] . BUB1 protein has an important role in cell division (mitosis) as a checkpoint regulator, so this (and functions in cell death regulation) could lead to many effects on bone and joint tissues [46] . AKT2 is a kinase enzyme regulator involved in cell signals; its function is strongly linked to T2D due to its involvement with insulin signaling, but it also plays a well established role in regulating the activity of bone forming cells [47] . CCR5 encodes a receptor that mediates cell response to a secreted chemokine factor, and it is particularly involved in immune cell inter-communication and in macrophages that regulate inflammation and bone formation. CCR5 blocking compounds have been developed as HIV-1 therapies [48] . It has recently been found to have unexpected roles in bone cells important in osteoporosis and joint damage [49] . A role has been suggested in diabetes relating to lipid formation. Lastly, ADCY2 encodes an adenyl cyclase enzyme that generates cyclic AMP, which is a crucial intracellular signaling molecule induced by many regulatory hormones important to bone [50] and metabolism [51] . In sum, these genes indicate a range of ways that T2D and the bone and joint diseases may interact, although in some cases further work is needed to establish a firm link. Clearly there must be other shared pathways that are not evident from our analysis, since it is unlikely that they will all be detectable in the datasets available, but the genes we identified, listed above, show a mix of well and poorly characterized disease links that might be expected. miRNAs are short 20-22 nucleotide long non-coding RNAs which regulate expression of gene transcripts (mRNAs) at post-transcriptional level. In this way, the miRNAs regulate the level of protein expression by inhibiting the mRNAs levels. There is evidence indicating the high potential of miRNAs as biomarkers for complex diseases [28] , [52] - [60] . Among the miRNA post-transcriptional regulators of the identified DEGs, it has been shown that mir-335-5p increases insulin resistance and suppresses pancreatic Îš cell secretion [61] . Moreover, overexpression of mir-335-5p can perturb insulin secretion [62] . Evidence suggests mir-16-5p is deregulated in retinal cells during hyperglycemia [63] . The significant overexpression of mir-16-5p was observed in hyperglycemia and euglycemia conditions in coronary heart disease [64] . It has been shown that circulating mir-26b-5p is dysregulated in T2D compared to control samples [65] . Moreover, significantly reduced expression of mir-26b-5p was observed in metformin treatments in T2D patients [66] indicating its involvement in pathogenesis, and its possible therapeutic targetting in the treatment of T2D. Involvement of the mir-124-3p in the progression and development of T2D has seen previously [67] . The involvement of the mir-218-5p, mir-98-5p, and mir-3135b with T2D and bone disease, however, has not been reported in the literature. However, overexpression of mir-29b-3p in T2D and in diarrhea-predominant irritable bowel syndrome is seen [68] , and it has been shown that diabetes affects tissue expression of mir-29c-3p [69] .
V. LIMITATIONS OF THE STUDY
Our analysis was performed using publicly available mRNA expression, so it was limited by what is currently accessible. We performed analyses of DEGs for use in gene enrichment approaches and cell signal pathway and Gene Ontology (GO) data; we were unable therefore to detect of DEGs that may be highly variable in their response to disease conditions between individuals, and we are limited by the current knowledge of cellular pathways. It should also be noted that pathway and GO analyses a large number of categories obtained were reduced by manual curation, making the approach not completely agnostic. While not difficult or time consuming, developing more analytical semantic methodologies to tackle this would better facilitate this approach and reduce operator bias as we have undertaken previously [20] . In addition to transcript analyses, we also found evidence for disease processes in the PPI data. This provided some confirmatory evidence for pathways identified through consideration of cell proteins and their interactions. However, this approach is necessarily incomplete as our understanding of and cataloging of PPI is an early stage due to the enormous number of protein motifs that exist.
VI. CONCLUSIONS
Our study demonstrates that an integrated approach to analyzing gene expression and gene function data can uncover novel relationships between diseases, potentially lead to new insights into the pathways that influence these conditions. We identified pathways that were common to T2D and the bone and joint conditions and identified ten genes. Their potential for pathogenic involvement was validated by evidence of disease-associated SNPs located in (or close to) them as well as the use of gene-disease association databases. The candidate genes identified were SYK, UCP3, ROR1, PPARG, BUB1, AKT2, CCR5, and ADCY2. The present study also identified significant TFs (GATA2, FOXC1, USF2, YY1, E2F1, JUN, RELA, CREB1, TFAP2A, NFB1) as well as miRNAs with the potential to regulate these pathways (namely mir-335-5p, mir-16-5p, mir-26b-5p, mir-124-3p, mir-218-5p, mir-98-5p, mir-29b-3p, mir-3135b, mir-29c-3p, mir-1-1). These factors have known disease involvement although many have not been validated in the interaction between T2D and the diseases examined here. Disease interaction pathways are very important since it indicates pathways of particular significance to the individual diseases, outside from a comorbidity context. Thus, the methods we used and pathway information identified show new ways to detect pathogenic mechanisms in common and complex diseases. His research interests include signal processing, especially, biomedical signal processing, big data analysis, image processing, time-frequency analysis, machine learning algorithms, deep learning, optimization, and computational intelligence in biomedical engineering.
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